Oral Glucose Absorption Enhanced in Early Metabolic Dysfunction-Associated Steatotic Liver Disease

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, affects nearly 25-30% of adults globally. This groundbreaking study investigates glucose metabolism alterations in early-stage MASLD, revealing surprising findings about intestinal glucose absorption that could reshape our understanding of disease progression.

Key Findings

Researchers discovered MASLD patients without fibrosis exhibited 34% higher glucose appearance rates at 1-hour post-glucose challenge (+318±142 µmol/kg, p=0.031), resulting in 52% greater total glucose absorption (+6.4±1.8 g, p=0.001). Crucially, accelerated glucose absorption showed the strongest association with MASLD prevalence – each standard deviation increase correlated with fivefold higher MASLD odds (OR 4.99, p=0.036), independent of BMI or other metabolic factors.

Metabolic Mechanisms

While MASLD patients displayed reduced glucose clearance relative to insulin levels, they maintained normal suppression of endogenous glucose production. This pattern indicates peripheral insulin resistance precedes hepatic insulin resistance in MASLD development. Surprisingly, gastric emptying rates showed no association with hepatic steatosis risk, suggesting intestinal absorption mechanisms rather than stomach emptying drive the observed glucose abnormalities.

Clinical Implications

These findings position enhanced intestinal glucose absorption as a potential early driver of MASLD pathogenesis. The study opens new therapeutic possibilities: modulating intestinal glucose transporters like SGLT1 might prevent MASLD progression before irreversible liver damage occurs. Current diabetes medications targeting glucose absorption (e.g., SGLT2 inhibitors) warrant investigation for MASLD management.

Research Methodology

Using sophisticated stable isotope techniques during 75g OGTTs, researchers precisely quantified glucose fluxes in MASLD patients without fibrosis and matched controls. A separate cohort underwent 13C-acetate breath testing to measure gastric emptying. All participants underwent comprehensive metabolic profiling including liver fat quantification through MRI-PDFF.

Conclusions and Future Directions

This research fundamentally shifts our understanding of MASLD pathogenesis, identifying intestinal glucose handling as a critical early abnormality. Future studies should explore whether dietary modifications targeting glucose absorption kinetics or repurposed diabetes medications can effectively interrupt MASLD progression. The findings highlight the intestine as a promising therapeutic target before advanced liver damage develops.